EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy

Christos Georgopoulos iD, Eleni Stamellou iD, Anila Duni, Lefkothea Dova, Georgios Vartholomatos iD, Ekaterini Siomou iD, Haralampos Milionis iD, Evangelia Dounousi iD

International Journal of Molecular Sciences · 13.08.2026 · 27 (16) · 7233

DOI: 10.3390/ijms27167233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.08.2026. Verfasst von Christos Georgopoulos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital of Ioannina, University of Ioannina, 45500 Ioannina, Greece. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, B-Lymphocytes, Antigens, CD20. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary membranous nephropathy (pMN) is an antibody-mediated podocytopathy, most commonly caused by autoantibodies against the M-type phospholipase A2 receptor (PLA2R1). Rituximab (RTX), an anti-CD20 monoclonal antibody, is a first-line treatment for moderate-to-high-risk pMN, inducing partial or complete remission in about 60% of patients within 24 months. However, treatment response varies considerably, and current biomarkers, including anti-PLA2R1 titers and peripheral B cell counts, have limited predictive value for non-response or relapse. Beyond B cell depletion, RTX exerts broader immunomodulatory effects by influencing T cell subsets, monocytes, and natural killer (NK) cells involved in antibody-dependent cellular cytotoxicity. This review examines the peripheral immune cell changes that accompany anti-CD20 therapy and their value as candidate biomarkers. Total CD19+ B cell depletion is the standard pharmacodynamic measure of drug effect but correlates only loosely with clinical outcome. A specific B cell reconstitution profile was associated with pending relapse. Class-switched memory B cells remain depleted during sustained remission, and their premature re-expansion has been associated with subsequent relapse. Regulatory T cells are reduced in active disease and rise within days of infusion in patients who later respond. The systemic inflammation response index, derived from the routine differential count, has been associated with both 6- and 12-month remission. These observations derive from small, mostly single-center cohorts using heterogeneous panels and different RTX regimens. On the available evidence, immune cell profiling cannot yet be recommended for routine disease monitoring, and larger prospective studies with standardized panels are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRituximabB-LymphocytesAntigens, CD20HumansBiomarkersReceptors, Phospholipase A2Autoantibodies

Stichwörter der Autor:innen

B cell depletionB cellsT regulatory cellsanti-PLA2R1 antibodiesbiomarkersimmune monitoringimmunological remissionimmunophenotypic profilingmembranous nephropathyrituximab

Substanzen

BiomarkersRituximabAntigens, CD20Receptors, Phospholipase A2AutoantibodiesPLA2R1 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, University Hospital of Ioannina, University of Ioannina, 45500 Ioannina, Greece.
  • Division of Nephrology and Rheumatology, RWTH Aachen University Hospital, 52074 Aachen, Germany.
  • Laboratory of Hematology, Unit of Molecular Biology, University Hospital of Ioannina, 45500 Ioannina, Greece.
  • Department of Pediatrics, University Hospital of Ioannina, 45500 Ioannina, Greece.
  • 1st Department of Internal Medicine, University Hospital of Ioannina, 45500 Ioannina, Greece.

ORCID-Profile: Christos Georgopoulos, Eleni Stamellou, Georgios Vartholomatos, Ekaterini Siomou, Haralampos Milionis, Evangelia Dounousi

Zitieren

APA

Georgopoulos, C., Stamellou, E., Duni, A., Dova, L., Vartholomatos, G., Siomou, E., Milionis, H., & Dounousi, E. (2026). Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy. International Journal of Molecular Sciences, 27(16), 7233. https://doi.org/10.3390/ijms27167233

Vancouver

Georgopoulos C, Stamellou E, Duni A, Dova L, Vartholomatos G, Siomou E, et al. Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy. International Journal of Molecular Sciences. 2026;27(16):7233. doi:10.3390/ijms27167233

BibTeX
@article{Georgopoulos2026,
  author = {Georgopoulos, Christos and Stamellou, Eleni and Duni, Anila and Dova, Lefkothea and Vartholomatos, Georgios and Siomou, Ekaterini and Milionis, Haralampos and Dounousi, Evangelia},
  title = {Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7233},
  doi = {10.3390/ijms27167233}
}
Kostenlos starten →